<DOC>
	<DOCNO>NCT01909557</DOCNO>
	<brief_summary>To assess effect Acetyl-L-Carnitine , probiotic antioxidant nutritional substance administration work productivity , daily activity , fatigue subject chronic hepatitis C treat Pegylated-Interferon-α2b Ribavirin .</brief_summary>
	<brief_title>Acetyl-L-Carnitine Supplementation During HCV Therapy With Peg IFN-α2b Plus Ribavirin : Effect Work Performance .</brief_title>
	<detailed_description />
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>Eligible patient worker 18 year age old , infected HCV quantifiable serum HCV RNA level ( determined polimerase chain reaction , COBAS AmpliPrep/COBAS TaqMan ROCHE ) . HCV infected population must elevate serum alanine transaminase level finding liver biopsy consistent chronic infection . Cirrhotic patient ChildPugh score less 7 eligible . Ineligible patient liver disease , well affected cancer , severe jaundice , pulmonary renal chronic disease , prostatic disease , autoimmune disease diabetes mellitus . Excessive use alcohol ( &gt; 20 g/die ) hepatotoxic drug . Other cause exclusion include decompensated cirrhosis , pregnancy , contraindication PegIFNa RBV therapy cardiopathy , hemoglobinopathy , hemocromatosis , major depression severe psychiatric pathological condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Acetyl-L-carnitine</keyword>
	<keyword>Interferons</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Fatigue</keyword>
</DOC>